The Discounted Cash Flow (DCF) valuation of Immunitybio Inc (IBRX) is (56.34) USD. With the latest stock price at 2.44 USD, the upside of Immunitybio Inc based on DCF is -2409.1%.
Based on the latest price of 2.44 USD and our DCF valuation, Immunitybio Inc (IBRX) is a sell. selling IBRX stocks now will result in a potential gain of 2409.1%.
Note: valuation result may not be accurate due to the company's negative cashflows.
| Range | Selected | |
| WACC / Discount Rate | 7.1% - 8.9% | 8.0% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (102.11) - (39.84) | (56.34) |
| Upside | -4284.9% - -1732.9% | -2409.1% |